2314. Burden of Respiratory Syncytial Virus (RSV) Infection Among Hospitalized Older Adults and Those with Underlying Chronic Obstructive Pulmonary Disease (COPD) or Congestive Heart Failure (CHF)
Evan J. Anderson(Emory University), Samadhan Jadhao(Centers for Disease Control and Prevention), Dilshad Rafi Ahmed(Emory University), Amer Bechnak(Emory University), Danielle Fayad(Emory University), Zayna Al-Husien(Emory University), Courtney McCracken(Emory University), Binh Ha(Emory University), Michelle Gaffney(Emory University), C. Stanley(Emory University), Wesley Washington(Emory University), Colleen Kraft(Emory University), Wendy Nesheim(Emory University), Jennifer E Spencer(Emory University), Jessica Traenkner(Emory University), Amy Muchinsky(Emory University), İnci Yıldırım(Emory University), Nadine Rouphael(Emory University), Carol Kao(Emory University), Natalia Schwartz(Emory University), Rody Bou Chaaya(Emory University), Ashley Tippett(Emory University), Lisa E. Emerson(Emory University), Larry Anderson(Emory University), Ifeyinwa Benyeogor(Emory University), Laila Hussaini(Emory University), Theda Gibson(Emory University), Laurel Bristow(Emory University), Kathryn Zaks(Emory University), Rijalda Deović(Emory University), Christina A. Rostad(Emory University), Kandra Greaves(Emory University), Andrew Cheng(Emory University), Sean O. Todd(Emory University), Luis W Salazar(Emory University), David L. Swerdlow(Pfizer (United States)), Yasmeen Agosti(Pfizer (United States)), Ana Drobeniuc(Emory University), Wensheng Li(Emory University), Aditya Kumar Singh(Emory University), M H Hart(Emory University), Ben Lopman(Emory University), Kathy Stephens(Emory University), Juton R. Winston(Emory University), Khuong Le(Emory University), Mohamed Munye(Emory University), Robin Hubler(Pfizer (United States))
Cited by 2
Related Papers
Hospitalized Patients with 2009 H1N1 Influenza in the United States, April–June 2009
|New England Journal of Medicine|2009|1.7k
H1N1 2009 influenza virus infection during pregnancy in the USA
|The Lancet|2009|1.4k
Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase
|New England Journal of Medicine|2021|661